News Briefing channel feed

FDA pins an­oth­er 'break­through' badge on Ab­b­Vie's vene­to­clax; Ex­press Scripts bats back at drug­mak­ers on pric­ing

7 years ago

Pfiz­er takes its op­tion in An­Tol­Rx deal; Se­cu­ra Bio scores ac­cess to $145M for can­cer drug launch­es

7 years ago

Pfiz­er stokes ru­mor mill with plan to raise $5B in debt; Lil­ly's CGRP Em­gal­i­ty wins speedy re­view for clus­ter headaches

7 years ago

As scruti­ny in­to drug prices in­ten­si­fies, Lil­ly launch­es half price Hu­ma­log; BioX­cel, Nek­tar ex­pand col­lab to in­clude Baven­cio in com­bo pan­cre­at­ic can­cer ther­a­py

7 years ago

The EMA of­fi­cial­ly va­cates its Lon­don HQ — next stop Am­s­ter­dam; CHMP backs ap­proval of 8 drugs

7 years ago

Kalei­do prices $75M IPO well be­low range; Sage rais­es $575M ahead of FDA de­ci­sion

7 years ago

Chi­na's CStone rais­es $285M in IPO; Ax­i­al rais­es $25M for mi­cro­bio­me work on Parkin­son's, autism

7 years ago

Am­i­cus blue­prints growth plans for Philly-based gene ther­a­py group; Cash-strapped Com­pu­gen re­struc­tures, cuts 35 staffers

7 years ago

CRISPR Ther­a­peu­tics treats first pa­tient with gene edit­ing tech; Am­i­cus nabs 'break­through' sta­tus for Pompe drug

7 years ago

Days af­ter In­di­v­ior launch­es au­tho­rized Sub­ox­one gener­ic, My­lan of­fers its copy­cat; In crowd­ed CGRP mar­ket, Alder sub­mits BLA

7 years ago

Al­lo­gene blue­prints a new man­u­fac­tur­ing com­plex for next-gen CAR-T; In­ovio spins out neoanti­gen up­start with $10.5M A round

7 years ago

Kalei­do sets terms for $100M IPO; Mallinck­rodt touts pos­i­tive PhI­II GVHD da­ta, cuts tri­al short

7 years ago

Ab­b­Vie scores speedy re­view for RA drug upadac­i­tinib; Mer­ck KGaA wins CRISPR patent

7 years ago

GW Phar­ma cannabi­noid to be test­ed for Alzheimer's ag­i­ta­tion; Acor­da rev­enue plum­mets as gener­ics evis­cer­ate its fran­chise

7 years ago

Mer­ck goes in deep­er with Keytru­da/Lyn­parza com­bo; PureTech un­veils stem cell ther­a­py start­up

7 years ago

Charles Riv­er drops $510M to bag non-clin­i­cal CRO; Mag­pie rais­es $14.8M Se­ries B to mod­ern­ize tra­di­tion­al Chi­nese meds

7 years ago

Chi­na vows to con­tin­ue speed­ing up drug ap­provals, ex­pand tax cuts; Sor­ren­to/Yuhan JV re­ceives $40M fi­nanc­ing

7 years ago

3SBio inks Chi­na deal with Boston-based Verseau; Er­ic Topol calls for dig­i­tal ed­u­ca­tion in NHS re­port

7 years ago

Equi­l­li­um's im­muno-in­flam­ma­to­ry drug wins FDA's or­phan drug sta­tus; Van­da sues FDA for man­dat­ing lengthy dog study

7 years ago

Split up the chair­man/CEO role at Al­ler­gan — ac­tivist in­vestor; Zo­genix files for FDA, EMA ap­proval of seizure drug

7 years ago

Am­gen, Sanofi back a round for re­al-world ev­i­dence plat­form tech; Dai­ichi Sanky­o's pex­i­dar­tinib se­cures speedy FDA re­view

7 years ago

Halozyme scores $30M in cash for its lat­est al­liance; Bernie Sanders takes aim at $375,000 rare dis­ease drug

7 years ago

EMA en­dors­es Teva's mi­graine drug; Dis­as­ter prone CTI Bio­Phar­ma re­scinds EU ap­pli­ca­tion for pa­cri­tinib

7 years ago

FDA stiff-arms Aveo on ti­vo, again; Sunovion Parkin­son's drug re­ject­ed

7 years ago
First page Previous page 52535455565758 Next page Last page
A service from the Financial Times